Search filters

Filters
Clear All

Phase

  • 1
  • 4
  • 13
  • 11
  • 3
  • 19
  • 54
  • 4
  • 1
  • 53

Found 54 neurology trials

A listing of neurology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Phase 2 Randomized Blinded study of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the treatment of Chronic Aphasia
18 years - 80 years
All genders
Phase 2
The Laboratory for Cognition and Neural Stimulation (LCNS) is currently recruiting individuals who have suffered from stroke and are now experiencing aphasia, a loss or impairment of language abilities, for a clinical trial. The purpose of this study is to determine if Transcranial Magnetic Stimulation (TMS), a form of non-invasive …
 Clinical Core Alzheimer's Disease Core Center (ABC)
75 years - 100 years
All genders
The study is at the Penn Memory Center at the University of Pennsylvania and is under the direction of David Wolk, M.D..  We are currently recruiting normal control participants ages 75 years and older. The purpose of this study is to collect, store and analyze cognitive data  and biological samples, …
 CHARM- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction
18 years - 99 years
All genders
Phase 3
Interventional
This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and …
 The Parkinsons Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort
18 years - 99 years
Accepts healthy volunteer
All genders
The purpose of this study is to continue to obtain information from people with and without Parkinson disease (PD) so that researchers may better understand how Parkinson disease progresses, in order to inform better treatments. The information collected in this study is for research and not for clinical care. This …
 Spironolactone for Regulating Blood Pressure after Intracerebral Hemorrhage
18 years - 99 years
All genders
Blood pressure treatment is important for all survivors of intracerebral hemorrhage (ICH). High blood pressure after ICH puts patients at high risk for future strokes and memory problems. Nearly all doctors agree that patients  who have had a brain hemorrhage should be treated with blood pressure medications. But doctors are …
 MG0004: A randomized  open-label extension study to investigate the long-term safety  tolerability  and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis
99 years or below
All genders
Phase 3
Rozanolixizumab is a humanized IgG4 monoclonal antibody that is being developed as an inhibitor of the activity of the neonatal Fc receptor (FcRn) for IgG. By blocking the activity of neonatal FcRn, rozanolixizumab accelerates the catabolism of antibodies and reduces the serum IgG concentration, including pathogenic IgG in MG patients, …
 CILT + HD-tDCS as a Potential Treatment for Primary Progressive Aphasia
45 years - 80 years
All genders
Phase 2
Primary Progressive Aphasia, or PPA, is a neurodegenerative disease that affects language abilities. A person with PPA may have difficulties speaking, understanding speech, reading, or writing, and these difficulties worsen over time.The purpose of this study is to determine whether a form of non-invasive brain stimulation called High-definition Transcranial Direct …
 PBFT02-001- Phase 1B Study to Assess a Single Dose of PBFT02 Delivered into Adult Subjects with Fronto-Temporal Dementia (FTD) and Mutations in the Progranulin Gene (GRN)
35 years - 75 years
All genders
Phase 1
This research is being done to study a new way to treat FTD in patients who have the GRN mutation. This process is called “gene therapy”. Gene therapy is an experimental technique that aims to replace the gene that is not working properly with a version of the gene that …
 TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
18 years - 99 years
All genders
Phase 4
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …
 A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ( (ADHERE)
18 years - 99 years
All genders
Phase 2
Study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.